1DD-LSD

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = (6aR,9R)-N,N-diethyl-6-methyl-4-dodecanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide

| image = 1DD-LSD_structure.png

| width = 220

| tradename =

| legal_AU =

| legal_BR =

| legal_CA =

| legal_DE =

| legal_UK =

| legal_US =

| legal_US_comment =

| legal_status =

| routes_of_administration =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 3028949-80-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII =

| PubChem = 170763787

| ChemSpiderID =

| C=32 | H=47 | N=3 | O=2

| smiles = CCCCCCCCCCCC(=O)N1C=C2C[C@@H]3C(=C[C@H](CN3C)C(=O)N(CC)CC)C4=C2C1=CC=C4

| StdInChI = 1S/C32H47N3O2/c1-5-8-9-10-11-12-13-14-15-19-30(36)35-23-24-21-29-27(26-17-16-18-28(35)31(24)26)20-25(22-33(29)4)32(37)34(6-2)7-3/h16-18,20,23,25,29H,5-15,19,21-22H2,1-4H3/t25-,29-/m1/s1

| StdInChIKey = CEPIQEJKLWHRTL-VAVYLYDRSA-N

}}

1DD-LSD (N1-dodecanoyl-lysergic acid diethylamide, SYN-L-004) is an acylated derivative of lysergic acid diethylamide (LSD). In animal studies it produces a weak head-twitch response but with 27x lower potency than LSD itself. It is being researched as a potential slow-onset, long lasting prodrug for LSD which is expected to have reduced psychoactive effects.{{cite journal | vauthors = Kavanagh PV, Westphal F, Pulver B, Elliott SP, Stratford A, Halberstadt AL, Brandt SD | title = Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD) | journal = Drug Testing and Analysis | volume = 17| issue = 1| pages = 101–109| date = April 2024 | pmid = 38569566 | doi = 10.1002/dta.3691 | doi-access = free | pmc = 11730435 }}{{cite patent | country = WO | number = 2024028495 | inventor = Stratford A, Williamson JP | assign = Synex Holdings BV | title = Prodrugs of Substituted Ergolines | url = https://patents.google.com/patent/WO2024028495A1/en?oq=WO2024028495 | pubdate = 8 February 2024 }}